Current rotavirus vaccines. Efficacy and cost-effectiveness;Aktuelle rotavirusimpfstoffe. Kriterien zur beurteilung des nutzens

Monatsschrift fur Kinderheilkunde

Volumn 153, Issue 9, 2005, Pages 831-837

  Forster, J ^a  

^a St Josefskrankenhaus   (Germany)

Author keywords

Cost effectiveness; Efficacy; Gastroenteritis; Oral vaccine; Rotavirus

Indexed keywords

ROTAVIRUS VACCINE;

CALCULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ENTERITIS; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNIZATION; MORTALITY; OUTPATIENT; REVIEW; ROTAVIRUS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 24944451507     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-005-1203-5     Document Type: Review

References (25)

1. Bishop RF, Davidson GP, Holmes IH et al. (1973) Evidence for viral gastroenteritis. N Engl J Med 289:1096-1097
2. Bishop RF, Barnes GL, Cipriani E et al. (1983) Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 309:72-76
3. Centers for Disease Control and Prevention (CDC) (2004) Suspension of rotavirus vaccine after reports of intussusception - United States, 1999. MMWR Morb Mortal Wkly Rep 53:786-789
4. Cezard JP, Duhamel JF, Meyer M et al. (2001) Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology 120:799-805
5. Clark HF, Lawley D, Shrager D et al. (2004) Infant immune response to human rotavirus serotype G1 vaccine candidate reassortant Wl79-9: different dose response patterns to virus surface proteins VP7 and VP4. Pediatr Infect Dis J 23:206-211
6. Desselberger U, McCrae MA (1994) The rotavirus genome. Curr Top Microbiol Immunol 185:31-66
7. Desselberger U (2005) RotaTeq (sanofi pasteur/Wistar Institute/Children's Hospital of Philadelphia). Curr Opin Invest Drugs 6:199-208
8. De Vos B, Vesikari T, Linhares AC et al. (2004) A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J [Suppl 10] 23:5179-5182
9. Ehlken B, Laubereau B, Karmaus W et al. (2002) Prospective population-based study on rotavirus disease in Germany. Acta Paediatr 91:769-775
10. Fischer TK, Bresee JS, Glass RI (2004) Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine [Suppl 1] 22:549-554
11. Flewett TH, Bryden AS, Davies H (1973) Virus particles in gastroenteritis. Lancet II:1497
12. Forster J, Frank HD, Henker H et al. (1999) RoMoD: Eine prospektive nationale Multizenterstudie zur Bedeutung von Rotaviruserkrankungen in Deutschland (Abstract). Monatsschr Kinderheilkd Suppl 2:S148
13. Fruhwirth M, Berger K, Ehlken B et al. (2001) Economic impact of community and nosocomially acquired rotavirus gastroenteritis in Austria. Pediatr Infect Dis J 20:184-188
14. Fruhwirth M, Karmaus W, Moll-Schuler I et al. (2001) A prospective evaluation of community acquired gastroenteritis in paediatric practices: impact and disease burden of rotavirus infection. Arch Dis Child 84:393-397
15. Ihorst G, Forster J, Petersen G et al. (2004) Determination of the population size in an epidemiological study with children. Methods Infect Med 43:479-482
16. Oh DY, Gaedicke G, Schreier E (2003) Viral agents of acute gastroenteritis in German children: prevalence and molecular diversity. J Med Virol 71:82-93
17. Poppe M, Ehlken B, Rohwedder A et al. (2002) Epidemiologie und Klinik von Rotavirus-Gastroenteritiden bei hospitalisierten Säuglingen und Kleinkindern in Deutschland. Monatsschr Kinderheilkd 1560:491-496
18. Santos N, Hoshino Y (2005) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15:29-56
19. Szajewska H, Mrukowicz JZ (2001) Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr [Suppl 2] 33:S17-S25
20. Tucker AW, Haddix AC, Bresee JS et al. (1998) Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 279:1371-1376
21. Velazquez FR, Matson DO, Calva JJ et al. (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335:1022-1028
22. Vesikari T, Isolauri E, Delem A et al. (1985) Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 107:189-194
23. Vesikari T, Ruuska T, Delem A et al. (1987) Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatr Infect Dis J 6:164-169
24. Vesikari T, Karvonen A, Puustinen L et al. (2004) Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 23:937-943
25. Vesikari T, Matson D, Dennehy P et al. (2005) Protection against Rotavirus gastroenteritis of mulitple serotypes by a pentavalent (human-bovine) reassortant rotavirus vaccine (PRV) (Abstract). Jahrestagung der European Society for Paediatric Infeclious Disesases, Valencia, Spanien